A novel thermosensitive in-situ gel of gabexate mesilate for treatment of traumatic pancreatitis: An experimental study

Abstract

Gabexate mesilate (GM) is a trypsin inhibitor, and mainly used for treatment of various acute pancreatitis, including traumatic pancreatitis (TP), edematous pancreatitis, and acute necrotizing pancreatitis. However, due to the characteristics of pharmacokinetics, the clinical application of GM still needs frequently intravenous administration to keep the blood drug concentration, which is difficult to manage. Specially, when the blood supply of pancreas is directly damaged, intravenous administration is difficult to exert the optimum therapy effect. To address it, a novel thermosensitive in-situ gel of gabexate mesilate (GMTI) was developed, and the optimum formulation of GMTI containing 20.6% (w/w) P-407 and 5.79% (w/w) P188 with different concentrations of GM was used as a gelling solvent. The effective drug concentration on trypsin inhibition was examined after treatment with different concentrations of GMTI in vitro, and GM served as a positive control. The security of GMTI was evaluated by hematoxylin-eosin (HE) staining, and its curative effect on grade II pancreas injury was also evaluated by testing amylase (AMS), C-reactive protein (CRP) and trypsinogen activation peptide (TAP), and pathological analysis of the pancreas. The trypsin activity was slightly inhibited at 1.0 and 5.0 mg/mL in GM group and GMTI group, respectively (P<0.05 vs. P-407), and completely inhibited at 10.0 and 20.0 mg/mL (P<0.01 vs. P-407). After local injection of 10 mg/mL GMTI to rat leg muscular tissue, muscle fiber texture was normal, and there were no obvious red blood cells and infiltration of inflammatory cells. Furthermore, the expression of AMS, CRP and TAP was significantly increased in TP group as compared with control group (P<0.01), and significantly decreased in GM group as compared with TP group (P<0.01), and also slightly inhibited after 1.0 and 5.0 mg/mL GMTI treatment as compared with TP group (P<0.05), and significantly inhibited after 10.0 and 20.0 mg/mL GMTI treatment as compared with TP group (P<0.01). HE staining results demonstrated that pancreas cells were uniformly distributed in control group, and they were loosely arranged, partially dissolved, with deeply stained nuclei in TP group. Expectedly, after gradient GMTI treatment, pancreas cells were gradually restored to tight distribution, with slightly stained nuclei. This preliminary study indicated that GMTI could effectively inhibit pancreatic enzymes, and alleviate the severity of trauma-induced pancreatitis, and had a potential drug developing and clinic application value.

Keywords

traumatic pancreatitis / trypsin inhibitor / gabexate mesylate / gabexate mesilate thermosensitive in-situ gel / treatment

References

[1] MenegattiE, BolognesiM, ScaliaS, et al. . Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis. J Pharm Sci, 1986, 75(12): 1171-1174 PMID: 3104578

[2] GiganteA, GasperiniML, BarbanoB, et al. . Gabexate mesylate as treatment in the course of ANCA-negative microscopic polyangiitis. Ren Fail, 2013, 35(5): 721-724 PMID: 23560992

[3] CortesiR, AscenziP, ColasantiM, et al. . Cross-enzyme inhibition by gabexate mesylate: formulation and reactivity study. J Pharm Sci, 1998, 87(11): 1335-1340 PMID: 9811486

[4] ColasantiM, PersichiniT, VenturiniG, et al. . Effect of gabexate mesylate (FOY), a drug for serine proteinase-mediated diseases, on the nitric oxide pathway. Biochem Biophys Res Commun, 1998, 246(2): 453-456 PMID: 9610382

[5] ValderramaR, Perez-MateoM, NavarroS, et al. . Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. Digestion, 1992, 51(2): 65-70 PMID: 1499875

[6] ManesG, ArdizzoneS, LombardiG, et al. . Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointest Endosc, 2007, 65(7): 982-987 PMID: 17531632

[7] MatsukawaY, NishinaritaS, HorieT, et al. . Anaphylaxis induced by gabexate mesylate. BMJ, 1998, 317(7172): 1563 PMCID: 28736 PMID: 9836656

[8] UekiT, OtaniK, KawamotoK, et al. . Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial. J Gastroenterol, 2007, 42(2): 161-167 PMID: 17351806

[9] LiXY, ZhuZJ, ChengAY. Characteristics of poloxamer thermosensitive in situ gel of dexamethasone sodium phosphate. Yao Xue Xue Bao (Chinese), 2008, 43(2): 208-213

[10] LiF, LiuY, DingY, et al. . A new injectable in situ forming hydroxyapatite and thermosensitive chitosan gel promoted by Na(2)CO(3). Soft Matter, 2014, 10(13): 2292-2303 PMID: 24795961

[11] YuanY, CuiY, ZhangL, et al. . Thermosensitive and mucoadhesive in situ gel based on poloxamer as new carrier for rectal administration of nimesulide. Int J Pharm, 2012, 430(1–2): 114-119 PMID: 22503953

[12] DingWM, LiM, LiGL, et al. . Thermosensitive in situ gel of boanmycin hydrochloride for injection. Yao Xue Xue Bao (Chinese), 2011, 46(6): 727-732

[13] ZhangW, WangG, SeeE, et al. . Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation. J Control Release, 2015, 203(2): 161-169 PMID: 25701612

[14] BujnakovaZ, DutkovaE, BalazM, et al. . Stability studies of AsS nanosuspension prepared by wet milling in Poloxamer 407. Int J Pharm, 2014, 478(1): 187-192 PMID: 25448581

[15] SenguptaA, DwivediN, KellySC, et al. . Poloxamer surfactant preserves cell viability during photoacoustic delivery of molecules into cells. Biotechnol Bioeng, 2015, 112(2): 405-415 PMID: 25182778

[16] RedheadHM, DavisSS, IllumL. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J Control Release, 2001, 70(3): 353-363 PMID: 11182205

[17] KorolenkoTA, JohnstonTP, DubrovinaNI, et al. . Effect of poloxamer 407 administration on the serum lipids profile, anxiety level and protease activity in the heart and liver of mice. Interdiscip Toxicol, 2013, 6(1): 18-25 PMCID: 3795317 PMID: 24170975

[18] ClarkJ, MontgomeryJ, SquiresR, et al. . Stabilization of a human recombinant factor VIII by poloxamer 188 in relation to polysorbate 80. Pharm Dev Technol, 2014, 4(2): 1-5

[19] HwangET, ChoJH. Acute gallstone pancreatitis misdiagnosed as acupuncture induced traumatic pancreatitis. Korean J Gastroenterol, 2013, 62(6): 379-381 PMID: 24511643

[20] HollandAJ, DaveyRB, SparnonAL, et al. . Traumatic pancreatitis: long-term review of initial non-operative management in children. J Paediatr Child Health, 1999, 35(1): 78-81 PMID: 10234641

[21] StreetDF. Duodenal obstruction associated with acute pancreatitis of traumatic origin. Br J Radiol, 1959, 32(1): 617-619 PMID: 13835169

[22] WarnerR f, OthersenH f, SmithCD. Traumatic pancreatitis and pseudocyst in children: current management. J Trauma, 1989, 29(5): 597-601 PMID: 2657083

[23] DixitP, SharmaV, SinghKR, et al. . Conservative management of a case of traumatic pancreatitis in childhood: a case report. Eur Rev Med Pharmacol Sci, 2014, 18(12): 1687-1689 PMID: 24992606

[24] FaroudyM, MosadikA, MouelhiS, et al. . The post-traumatic pancreatitis: about four cases. Ann Fr Anesth Reanim, 2006, 25(6): 652-656 PMID: 16546346

[25] SchmittenbecherPP, RappP, DietzHG. Traumatic and non-traumatic pancreatitis in pediatric surgery. Eur J Pediatr Surg, 1996, 6(2): 86-91 PMID: 8740130

[26] DebiU, KaurR, PrasadKK, et al. . Pancreatic trauma: a concise review. World J Gastroenterol, 2013, 19(47): 9003-9011 PMCID: 3870553 PMID: 24379625

[27] J Surg Case Rep, 2014, 2014(12

[28] FreyrieA, MeleM, FaggioliGL, et al. . Pancreatic injury during AAA repair: a comparison between EVAR and open repair. Eur Rev Med Pharmacol Sci, 2012, 163): 370-375 PMID: 22530355

[29] FilinVI, TolstoiAD, SalamatinBN, et al. . Pancreatic injuries and traumatic pancreatitis. Vestn Khir Im I I Grek, 1982, 129(8): 66-72 PMID: 7135763

[30] PirollaEH, de Barros FilhoTE, Godoy-SantosAL, et al. . Association of acute pancreatitis or high level of serum pancreatic enzymes in patients with acute spinal cord injury: a prospective study. Spinal Cord, 2015, 53(6): 495 PMID: 25665541

[31] RheinheimerJ, ZiegelmannPK, CarlessiR, et al. . Different digestion enzymes used for human pancreatic islet isolation: a mixed treatment comparison (MTC) meta-analysis. Islets, 2014, 6(4): e977118 PMID: 25437379

[32] ShafiqN, RanaS, BhasinD, et al. . Pancreatic enzymes for chronic pancreatitis. Cochrane Database Syst Rev, 2009

[33] TrangT, ChanJ, GrahamDY. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century. World J Gastroenterol, 2014, 20(33): 11 467-11 485

[34] In brief: pancreatic enzyme products.. Med Lett Drugs Ther, 2011, 53(1357): 12

[35] FerroneM, RaimondoM, ScolapioJS. Pancreatic enzyme pharmacotherapy. Pharmacotherapy, 2007, 27(6): 910-920 PMID: 17542772